ESR1 and breast carcinoma: Whereas SAHA, an HDAC inhibitor, was reported to enhance ERα degradation through a CHIP-mediated proteasomal pathway in breast cancer MCF7 cells, suggesting the positive cross-talk between CHIP and SAHA in ER-positive breast cancers [82].